Ocular Therapeutix (NASDAQ: OCUL)
Ocular Therapeutix Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ocular Therapeutix Company Info
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
News & Analysis
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky.
Why Shares of Ocular Therapeutix Jumped This Week
A promising report of a therapy in a phase 1 trial gave the stock a lift.
Here's Why Ocular Therapeutix Stock Is Sinking Today
The company's experimental dry-eye treatment produced some disappointing clinical trial results.
This Exciting Biopharma Could Earn You 55% in 12 Months
When patients see more clearly, so too should investors.
4 Reasons I Just Bought Ocular Therapeutix Stock
This company's drug delivery technology just isn't getting the appreciation it deserves right now.
Can Ocular Therapeutix Reach Its Full Potential?
The biotech has a ways to go.
3 Top Healthcare Stocks to Buy Now
Find out how shares of these disruptive businesses could make you rich.
3 Reasons to Buy Ocular Therapeutix Stock Right Now
There are a few reasons this could be the best biotech stock you can buy at the moment.
Valuation
Earnings Transcripts
Ocular Therapeutix (OCUL) Q1 2020 Earnings Call Transcript
OCUL earnings call for the period ending March 31, 2020.
Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript
OCUL earnings call for the period ending December 31, 2018.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.